Regeneron Pharmaceuticals Inc. ($REGN) Stock Forecast: Down 5.5% Today

What is Regeneron Pharmaceuticals Inc.?

Regeneron Pharmaceuticals (NASDAQ: REGN) is a leading biotechnology company known for its innovative treatments in various therapeutic areas.

Why is Regeneron Pharmaceuticals Inc. going down?

REGN stock is down 5.5% on Mar 12, 2025 13:46

• The bearish movement in REGN today could be attributed to profit-taking by investors after the stock's significant outperformance over the past 20 years.
• Positive discussions about the impressive historical returns of REGN might have influenced investors to sell their positions today, resulting in downward pressure on the stock.
• Market participants could be reevaluating their positions in REGN due to its high market capitalization, leading to a temporary decline in the stock price.

REGN Price Chart

REGN Technical Analysis

REGN News

If You Invested $1000 In This Stock 20 Years Ago, You Would Have This Much Today - Regeneron Pharmaceuticals ( NASDAQ:REGN )

Regeneron Pharmaceuticals REGN has outperformed the market over the past 20 years by 19.54% on an annualized basis producing an average annual return of 27.57%. Currently, Regeneron Pharmaceuticals has a market capitalization of $78.92 billion.

https://www.benzinga.com/insights/news/25/03/44265606/if-you-invested-1000-in-this-stock-20-years-ago-you-would-have-this-much-today

Trending Today

Sui ($SUI) Crypto Forecast: Up 6.0% Today

Pepe ($PEPE) Crypto Forecast: Up 5.0% Today

dogwifhat ($WIF) Crypto Forecast: Up 13.7% Today

Bonk ($BONK) Crypto Forecast: Up 5.3% Today

Bitcoin SV ($BSV) Crypto Forecast: Up 45.8% Today

SolarEdge Technologies, Inc. ($SEDG) Stock Forecast: Up 5.0% Today

Stox ($STX) Crypto Forecast: Up 5.2% Today

Intel Corporation ($INTC) Stock Forecast: Down 6.6% Today

Aon plc Class A (UK) ($AON) Stock Forecast: Down 8.2% Today

T-Mobile US Inc. ($TMUS) Stock Forecast: Down 11.9% Today

Regeneron Pharmaceuticals Inc. Price History

06.00.2025 - REGN Stock was up 1.9%

• Despite signs of bearish sentiment from financial giants through unusual options activity, the stock displayed a robust bullish movement, contrary to expectations.
• The divergence between options activity and market performance could be due to favorable developments or news within the company that overshadowed the bearish sentiment.
• Positive clinical trial outcomes, regulatory approvals, or strong financial results may have influenced the upward movement in REGN's stock price.
• Investors potentially responded well to the company's strategic choices or growth outlook, contributing to the surprising bullish movement despite the bearish options activity.

31.09.2024 - REGN Stock was down 9.7%

• Despite reporting better-than-expected third-quarter results with increased earnings and revenue, REGN experienced a bearish movement.
• The market may have reacted negatively due to investors possibly having higher expectations or concerns about future growth prospects.
• Even though the company's performance was strong, market sentiment and external factors could have influenced the stock's decline.
• It's essential for investors to consider both the company's financial results and market dynamics when analyzing stock movements.

15.10.2024 - REGN Stock was down 5.4%

• The FDA accepting the resubmission of the supplemental biologics license application for Regeneron's Dupixent indicates a potential positive development for the company.
• However, the market might have reacted bearishly due to uncertainty surrounding the outcome of the FDA review process.
• The investor conference presentations could have failed to provide significant new insights or positive catalysts, contributing to the bearish movement in the stock price.
• Investors might be cautious about the competitive landscape in the inflammatory skin disease market, leading to profit-taking and a downward trend in REGN's stock.

04.01.2025 - REGN Stock was up 5.1%

• Regeneron reported impressive Q4 earnings, with adjusted EPS surpassing estimates and sales exceeding expectations, driven by growth in key products like Eylea and Libtayo.
• The company's decision to introduce a dividend and implement a stock buyback program likely enhanced investor confidence in its future prospects.
• Despite facing legal challenges and lawsuits related to securities law violations, the favorable earnings report and strategic financial moves overshadowed these issues, resulting in a rise in the stock price.
• Anticipation among investors for a strong performance in Dupixent and Eylea HD in the upcoming earnings report led to increased positivity and contributed to the bullish outlook for Regeneron Pharmaceuticals.

04.01.2025 - REGN Stock was up 2.8%

• The bullish movement in REGN's stock could be attributed to investors' anticipation of a positive earnings report for the fourth quarter of 2024.
• Despite facing a class-action lawsuit for securities law violations, investors seem optimistic about REGN's future performance, possibly due to the potential success of its key drugs like Dupixent and Eylea HD.
• The lawsuit may have already been factored into the stock price, leading investors to focus more on the company's operational performance and growth prospects.
• Overall, the market seems to be reacting favorably to REGN's potential earnings beat and the strength of its product portfolio, overshadowing the legal challenges the company is currently facing.

05.01.2025 - REGN Stock was up 7.2%

• REGN experienced a strong bullish movement after reporting better-than-expected Q4 earnings, with adjusted EPS of $12.07 surpassing consensus estimates.
• The initiation of a dividend program and additional stock buyback program by Regeneron further boosted investor confidence in the company's financial stability and growth prospects.
• Despite a slight decline in Eylea sales in the United States due to competition, the overall sales growth of 10% to $3.79B and the surge in sales of other drugs like Libtayo contributed to the positive market response.
• The lawsuit against Regeneron for securities law violations may have initially caused some uncertainty, but the strong earnings report and strategic financial decisions overshadowed these concerns, leading to the bullish market movement.

31.09.2024 - REGN Stock was down 10.8%

• REGN's Q3 earnings and revenues exceeded expectations, attributed to robust sales of Eylea HD and Dupixent.
• The market exhibited a bearish reaction post-results, possibly due to profit-taking following a period of solid performance.
• Concerns around REGN's growth sustainability and industry competition might have fueled investor caution, contributing to the bearish sentiment.
• Short-term dynamics appear to influence the market's sentiment towards REGN, possibly diminishing focus on the company's solid fundamentals and product range.

09.11.2024 - REGN Stock was up 2.9%

• Despite concerns about Navitas Semiconductor's financial performance, investors seem to be more focused on the positive outlook for LandBridge and Eli Lilly, which could be boosting overall market confidence.
• The bullish movement in REGN may also be attributed to positive developments in the biotechnology sector or specific company news that has driven investor optimism.
• An endorsement of LandBridge as a 'winner' could be influencing market sentiment positively, potentially spilling over to other related stocks like REGN.
• Overall, the bullish movement in REGN today could be a result of a combination of sector-specific tailwinds, positive company news, and investor sentiment influenced by comments from a market analyst.

19.11.2024 - REGN Stock was down 5.2%

• The bearish movement in REGN today could be attributed to Eylea HD showing non-inferiority to Eylea in a phase III study, raising concerns about potential competition within Regeneron's product line.
• The announcement of REGN's presentation at the J.P. Morgan Healthcare Conference might not have met market expectations for clear growth strategies or developments.
• The successful results of Eylea's higher dose formulation in treating another form of retinal disease might have been overshadowed by concerns about declining Eylea sales. This mixed performance of their lead drug could have influenced the bearish sentiment surrounding REGN.
• Overall, the market's reaction to recent events and REGN's performance this year, with a 15.5% decline, suggests investors are adopting a cautious approach, waiting for clearer signals of growth and stability before making significant moves in the stock.

13.00.2025 - REGN Stock was up 5.2%

• Despite facing a 35.6% decline in the past six months due to Eylea's sales drop, REGN saw a surge today, possibly indicating a shift in investor sentiment.
• The class action lawsuits against REGN might have initially impacted the stock negatively, but the market's reaction today suggests investors are optimistic about the company's future prospects.
• The upcoming financial results announcement on February 4, 2025, could be generating positive anticipation among investors, leading to the bullish movement in REGN's stock price.

12.02.2025 - REGN Stock was down 5.5%

• The bearish movement in REGN today could be attributed to profit-taking by investors after the stock's significant outperformance over the past 20 years.
• Positive discussions about the impressive historical returns of REGN might have influenced investors to sell their positions today, resulting in downward pressure on the stock.
• Market participants could be reevaluating their positions in REGN due to its high market capitalization, leading to a temporary decline in the stock price.

07.02.2025 - REGN Stock was up 5.1%

• REGN stock showed a strong bullish movement today.
• The positive recommendation for conditional marketing authorization for REGN's linvoseltamab to treat multiple myeloma is likely responsible for boosting investor confidence in the company's drug pipeline.
• This development hints at a possible new revenue source for Regeneron, leading to increased optimism among investors and influencing the bullish market movement.
• Investors may interpret this event as a significant milestone for Regeneron's expansion into the oncology market, contributing to the positive sentiment surrounding the stock.